ARCA biopharma, Inc. and Dr. Michael Bristow, President, Chief Executive Officer and a member of the board of directors of ARCA have mutually agreed to conclude Dr. Bristow's employment and service as a director, effective April 3, 2024. In connection with Dr. Bristow's separation, ARCA and Dr. Bristow entered into a separation agreement on April 3, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.47 USD | +2.91% | +6.44% | +104.12% |
04-25 | ARCA biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-19 | North American Morning Briefing : Stock Futures -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
+104.12% | 48.92M | |
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- ABIO Stock
- News ARCA biopharma, Inc.
- ARCA biopharma, Inc. Announces Separation of Michael Bristow, Chief Executive Officer